MEMORANDUM FOR SGO
ATTN: CAPT ADRIAN R BERSABE

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled **Chronic Lymphocytic Leukemia (CLL) as an Unusual Cause of Rapid Airway Compromise** presented at/published to *Case Reports in Oncologic Medicine (Journal & Abstract)* in accordance with MDWI 41-108, has been approved and assigned local file #17169.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Hout, office phone: 210-292-8029; email address: alice.houty.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

*Warrior Medics — Mission Ready — Patient Focused*
INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSCE); SG5 O&M; SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59ordpubpres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDWPA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CCE. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-100, Presentation and Publication of Medical and Technical Papers, for additional information.

11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

   For presentations before professional societies and organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.
   
   If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.
   
   If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business within the government, then your presentation should have an ethics review.
   
   If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.
   
   If you are receiving an honorarium or payment for speaking, a legal ethics review is required.
   
   If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-6750/3366, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
**PROTOCOL TITLE:** Chronic lymphocytic leukemia (CLL) as an Unusual Cause of Rapid Airway Compromise

**1. TO:** CLINICAL RESEARCH

**2. FROM:** (Author's Name, Rank, Grade, Office Symbol)

ADRIAN R. BERSABE, CAPT., O3, SGO

**3. GME/GHSE STUDENT:** □ YES  □ NO

**4. PROTOCOL NUMBER:** N/A

**5. IS THIS MATERIAL CLASSIFIED?** □ YES  □ NO

**6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:**

**7. FUNDING RECEIVED FOR THIS STUDY?** □ YES  □ NO

**8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES?** □ YES  □ NO

**9. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.?** □ YES  □ NO

**11. MATERIAL IS FOR:** □ DOMESTIC RELEASE  □ FOREIGN RELEASE

**11a. PUBLICATION/JOURNAL:** (List intended publication/journal.)

Case Reports in Oncologic Medicine

**11b. PUBLISHED ABSTRACT (List intended journal.)**

Case Reports in Oncologic Medicine

**11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)**

**11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)**

**11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)**

**12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?** □ YES  □ NO

**13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC**

DATE

30 March 2017

**14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)**

BERSABE, ADRIAN, R.; adrian.r.Bersabe.mil@mail.mil

**15. DUTY PHONE/PAGER NUMBER**

210-513-0759

**16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.**

<table>
<thead>
<tr>
<th>LAST NAME, FIRST NAME AND M.I.</th>
<th>GRADE/RANK</th>
<th>SQUADRON/GROUP/OFFICE SYMBOL</th>
<th>INSTITUTION (if not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrian. R. Bersabe</td>
<td>O3/Capt</td>
<td></td>
<td>959 CSPS</td>
</tr>
<tr>
<td>Joshua T. Romain</td>
<td>O3/Capt</td>
<td></td>
<td>959 CSPS</td>
</tr>
<tr>
<td>Erin E. Ezell</td>
<td>O4/Maj</td>
<td></td>
<td>Eglin Hospital, Eglin AFB</td>
</tr>
<tr>
<td>John S. Renshaw</td>
<td>O5/LtCol.</td>
<td></td>
<td>59 MDW</td>
</tr>
</tbody>
</table>

**17. IS A 502 ISG/AC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)?** □ YES  □ NO

**18. AUTHOR'S PRINTED NAME, RANK, GRADE**

Adrian R. Bersabe, Capt., O3

**19. AUTHOR'S SIGNATURE**

BERSABE, ADRIAN R. 117623160

**20. DATE**

21 March 2017

**21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE**

John S. Renshaw, LtCol., 05

**22. APPROVING AUTHORITY'S SIGNATURE**

**23. DATE**

4/4/17
**Single subject case study with appropriate disclaimers. Approved**
Title: Chronic lymphocytic leukemia (CLL) as an Unusual Cause of Rapid Airway Compromise

Authors:

1Adrian R. Bersabe, MD, Department of Medicine: Hematology/Oncology, San Antonio Military Medical Center, Fort Sam Houston, TX

2Joshua T. Romain, MD Department of Medicine, San Antonio Military Medical Center, Fort Sam Houston, TX

3Erin E. Ezzell, DO, Department of Medicine: Hematology Oncology, Eglin Hospital, Eglin AFB, FL

1John S. Renshaw, MD, Department of Medicine: Hematology/Oncology, San Antonio Military Medical Center, Fort Sam Houston, TX

Corresponding author:

Adrian R. Bersabe
3551 Roger Brooke Drive
Fort Sam Houston, TX 78234
210-916-0736 (office)
210-539-8809 (fax)
adrian.r.bersabe.mil@mail.mil
Abstract:

Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of non-Hodgkin's lymphoma (NHL) in Western countries predominantly affecting adults over age 65. CLL is commonly indolent in nature but can present locally and aggressively at extranodal sites. Although CLL may commonly present with cervical lymphadenopathy, manifestations in non-lymphoid regions of the head and neck is not well-described. CLL causing upper airway obstruction is even more uncommon. We describe a case of a patient with known history of CLL and stable lymphocytosis that developed an enlarging lymphoid base of tongue (BOT) mass resulting in rapid airway compromise.

Introduction:

Chronic Lymphocytic Leukemia (CLL) is the most common form of adult Non-Hodgkin’s Lymphoma (NHL). This mature B-cell neoplasm has an incidence rate of 4.6 per 100,000 people in the United States each year [1, 2, 3, 4, 5]. This disease process predominantly affects adults over age 65 and is more common in men. CLL has an extremely variable course of presentation ranging from asymptomatic lymphocytosis to painless lymphadenopathy, hepatomegaly, splenomegaly, cytopenias, and infections. Patients may also present with the typical "B" symptoms of unintentional weight loss, fever, and drenching night sweats [3, 4, 5]. Rapid progression with transformation into an aggressive, high-grade NHL is known as Richter syndrome and may occur in up to 10% of patients with CLL [6].

Although indolent in nature, CLL can present as locally aggressive extranodal mass resulting in symptoms depending on the location and extent of tissue involvement [7]. We present a unique case of a patient with known CLL and stable lymphocytosis for many years that later developed rapid airway compromise from an enlarging lymphoid base of tongue (BOT) mass which was identified as non-transformed CLL.
Case Presentation:

A 62-year-old woman with untreated Rai stage II CLL was initially diagnosed in January 2007. At that time she was found to have an absolute lymphocyte count (ALC) of 8 g/dL, mild splenomegaly, and mild abdominal lymphadenopathy. She was otherwise asymptomatic. Bone marrow biopsy confirmed a monoclonal B-cell population of lymphocytes with CDS and dim CD23 co-expression. Results at that time also showed normal cytogenetics, FISH negative for 11q deletion, 13q deletion, p53 deletion and trisomy 12. β-2 microglobulin was 2.4 mg/L and ZAP 70 was normal. She underwent close observation for several years. During this period of surveillance, she did not experience any recurrent bacterial infections, and serial monitoring of quantitative immunoglobulins demonstrated IgG levels greater than 500mg/dL.

However, in December 2011, she presented to the emergency department for complaints of feeling a globus sensation over the span of forty-eight hours. This symptom was associated with dysphagia, diffuse myalgias, high-grade fevers, and shortness of breath. ALC at the time remained stable at 8.5 g/dL with no evidence of anemia or thrombocytopenia. Lactate dehydrogenase (LDH) was normal at 188 IU/L and β-2 microglobulin was elevated to 3.3 mg/L. CT scan of the neck demonstrated a large heterogeneously enhancing 4.1cm mass involving the palatine tonsils causing severe narrowing of the hypopharynx. She was admitted and quickly developed worsening shortness of breath and stridor prompting otolaryngology consultation for urgent tracheostomy placement.

The BOT mass was biopsied at the time of tracheostomy placement. The pathology specimen demonstrated squamous mucosa with acute inflammation and reactive hyperplasia most consistent with bacterial infection and lymphoid tissue hyper-reactivity. No monoclonal lymphocyte population was identified. Furthermore, no pathogens were isolated from biopsy specimen, blood cultures, or
sputum cultures, and CRP was normal at 0.06 mg/dL. However, the decision was made to empirically treat with ten days of moxifloxacin. After completing her course of antibiotics, she noted complete resolution of her globus sensation, dysphagia, fevers, and myalgias.

Although her symptoms had completely resolved, a CT of the neck was repeated and showed persistence of the BOT mass six weeks after her initial admission for rapid airway compromise. Direct laryngoscopy was thus performed, and repeat biopsy of the mass now showed a monomorphic population of CD20+, CD5+, CD23+, and cyclin D1 negative lymphocytes consistent with patient’s previous diagnosis of CLL (Fig. 1). PET-CT to evaluate for other sites of disease showed FDG-avid lingular tonsillar irregularity and hypertrophy (SUV of 4.9, mediastinal blood pool activity with SUV of 1.5) with numerous sub-centimeter cervical lymph nodes that were only mildly FDG-avid (maximum SUV of 2.2). There was no other evidence of lymphadenopathy, and the spleen was not significantly enlarged. Given the patient’s initial presentation with rapid deterioration resulting in respiratory failure, Richter transformation was considered. Again, however, biopsy results did reveal transformation into a more aggressive NHL clone, and PET-CT showed localized disease which both argue against this phenomenon, however.

Fig 1:

![Image](image_url)

Fig 1. Immunohistochemical staining demonstrating a monomorphic population of CD20 positive lymphocytes with co-expression of CD5 typical of CLL.
She was started on chemotherapy with bendamustine and rituximab (BR) with a dramatic anatomic response after two cycles (Fig. 2) and near complete response (CR) after four cycles when tracheostomy was removed. She eventually completed 6 cycles of BR in October 2012 and achieved a CR with complete marrow recovery confirmed by bone marrow biopsy. She has been closely followed in the outpatient setting with no evidence of disease recurrence as of March 2017.

**Fig 2:**

Fig 2. Interval change in size of BOT mass on contrasted CT scan of the head and neck before (a1 and a2) and after (b1 and b2) two cycles of Bendamustine and Rituximab.
Discussion:

Current literature regarding the presentation of CLL of the head and neck is very limited [5]. Although lymphomas often present in Waldeyer’s ring of the pharynx, involvement of the oral cavity, larynx, and hypopharynx is exceedingly uncommon [7]. A rare case of palatal infiltration has been described by Vibhute, et al. When lymphomas present in the oral cavity, some more common manifestations include gingival hypertrophy, petechial hemorrhage or ecchymosis, infection, ulceration and necrosis [8]. Most presentations of CLL of the head and neck manifest as cervical lymphadenopathy or skin involvement, with the latter predicting poor prognosis [5, 8].

Upper airway obstruction resulting from CLL is even more uncommon. Although rare, airway obstruction is more often the result of mass effect from hilar and mediastinal adenopathy [4]. More common malignant causes of upper airway obstruction include locally advanced lung cancer as well as metastases from thyroid, skin, head and neck, or breast cancer [7, 9]. Regardless of the exact etiology, the approach to malignant airway obstruction is variable across different clinicians and institutions and may involve single or multi-modality therapies [9].

The possibility of Richter syndrome with transformation of CLL into a large cell lymphoma was indeed entertained after it was later discovered that the underlying etiology of the patient’s respiratory decline was due to CLL. Richter transformation can occur in 3 to 10% of patients with CLL. Underlying infections have also been implicated in triggering these transformations [6]. Although it is still debated, it is theorized that the Epstein-Barr virus (EBV) has a role in Richter transformation through direct oncogenic stimulation or through mitogenic and activating signals within the microenvironment. Rapid clinical deterioration is often a hallmark of Richter transformation similar to the presentation of our patient. The usual presentation of this aggressive transformation often includes increasing
lymphocytosis, progressive cytopenias, elevated LDH, and sometimes diffuse, bulky lymphadenopathy [11]. Other than rapid respiratory decline, our patient did not have any of these findings, and a repeat biopsy result confirmed CLL.

Another clinical challenge faced in this particular case was the presentation of a likely overlying infection given acuity of onset, fevers, and initial biopsy denoting acute inflammation and reactive lymphoid hyperplasia with a lack of monoclonal B-cell population. Infections are indeed the leading cause of death in patients with CLL and can account for up to 60% of disease-related mortality. This is due to a constellation of immune defects involving T-cell dysfunction, reduced complement levels, hypogammaglobulinemia, and impaired B-cell function [11]. A superimposed infection could not be ruled out in this case, given the initial presentation with acute inflammatory changes and lymphoid hyperplasia on biopsy and clinical improvement with antibiotics. In fact, Salem et al. describes four cases of patient with CLL who presenting with B-symptoms and laboratory and imaging findings concerning for progression of their lymphoma but were instead found to have a superimposed Herpes simplex viral infection. Our patient presenting symptoms concerning for an underlying infection, but biopsy and microbiology work-up did not reveal a definitive pathogen.

CLL and other indolent extranodal lymphomas (ENL) are highly responsive to systemic therapy. For this reason, systemic therapy is considered the primary treatment modality for aggressive, localized ENL, unless they are considered unfit for or refuse such treatment. The treatment regimen of Bendamustine and Rituximab was chosen in this case due to high response rates and favorable safety profile [3]. However, low-dose radiation therapy is highly effective and may be considered for patients with stage IIIE/IV disease for palliative intent [7].

In summary, this case illustrates an unusual presentation of CLL causing airway compromise in a patient with a non-transformed indolent lymphoma. Prompt recognition is required to institute early
intervention. Initial biopsy findings were concerning for a possible bacterial infection in this patient with known CLL. However, the superimposed bacterial infection may have complicated the clinical picture. Nevertheless, cases of infection mimicking CLL progression have been described and accurate identification of the underlying etiology is essential in order to make appropriate treatment decisions.

This patient responded very well and achieved a CR after completing six cycles of BR. She has maintained a CR for over four years after completing cytotoxic therapy.
References:


2016 Dec 1, doi: 10.1111/his.13137. [Epub ahead of print]

**Competing Interests:**

No competing financial or non-financial interests exist in the preparation of this manuscript.

**Disclaimer statement:** The views expressed are those of the authors and do not reflect the official views or policy of the Department of Defense or its Components.